{"entity":{"id":"cysltr2","kind":"target","name":"CYSLTR2","aka":["cysteinyl leukotriene receptor 2","Cysteinyl leukotriene receptor 2","CysLT(2)","CYSLT2R"],"tldr":"CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.","summary":"Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Cervical Adenocarcinoma, Uveal Melanoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18274","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18274"},{"label":"UniProt Q9NS75","url":"https://www.uniprot.org/uniprotkb/Q9NS75/entry"},{"label":"NCBI Gene 57105","url":"https://www.ncbi.nlm.nih.gov/gene/57105"},{"label":"Ensembl ENSG00000152207","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152207"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["cervical","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CYSLTR2","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:18274","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18274","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9NS75","url":"https://www.uniprot.org/uniprotkb/Q9NS75/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CYSLTR2","url":"https://civicdb.org/features/13648","note":"1 evidence items, 0 assertions, 1 variants; diseases: Cancer (GraphQL API, CC0)"},{"label":"IntOGen CYSLTR2","url":"https://www.intogen.org/search?gene=CYSLTR2","note":"driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"few-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CYSLTR2: RNA tissue enhanced (placenta 22 nTPM, seminal vesicle 15 nTPM); blood lineage lineage enriched (granulocytes 90 nTPM); high antibody staining in 14 normal tissues; highest cancer staining prostate cancer (12 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q9NS75","url":"https://www.uniprot.org/uniprotkb/Q9NS75/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CYSLTR2","url":"https://civicdb.org/features/13648","note":"1 evidence items, 0 assertions, 1 variants; diseases: Cancer (GraphQL API, CC0)"},{"label":"IntOGen CYSLTR2","url":"https://www.intogen.org/search?gene=CYSLTR2","note":"driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas CYSLTR2 tissue","url":"https://www.proteinatlas.org/ENSG00000152207-CYSLTR2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000152207 associations","url":"https://platform.opentargets.org/target/ENSG00000152207/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:18274","ensembl":"ENSG00000152207","uniprot":"Q9NS75","entrez":"57105","firstDescribed":2000,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Takasaki et al, Biochem. Biophys. Res. Commun, 2000, \"The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/10913337/","biology":"Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. Location: Cell membrane (UniProt). Locus 13q14.2 (HGNC).","whereFound":["Cervical cancer: IntOGen driver in 1 cohort (CEAD)","Uveal melanoma: IntOGen driver in 1 cohort (UM)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/cysltr2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}]}}